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In Denmark, both influenza A(H1N1)pdm09 and influ-
enza B co-circulated in the 2015/16 season. We esti-
mated the vaccine effectiveness (VE) of the trivalent 
influenza vaccine in patients 65 years and older using 
the test-negative case–control design. The adjusted 
VE against influenza A(H1N1)pdm09 was 35.0% (95% 
confidence interval (CI): 11.1–52.4) and against influ-
enza B 4.1% (95% CI: −22.0 to 24.7). The majority 
of influenza A(H1N1)pdm09 circulating in 2015/16 
belonged to the new genetic subgroup subclade 6B.1.
In Denmark, both influenza A(H1N1)pdm09 and influ-
enza B co-circulated in the 2015/16 season. The tri-
valent influenza vaccine (TIV) did not include the 
circulating influenza B Victoria lineage and there is 
evidence in Europe for genetic evolution of the circulat-
ing influenza A(H1N1)pdm09 virus [1]. We estimated the 
influenza vaccine effectiveness (VE) in people aged 65 
years and older. In addition, we describe the genetic 
and antigenic characteristics of the influenza A(H1N1)
pdm09 variant and the influenza B strain circulating in 
Denmark.
Data for vaccine effectiveness estimation
In the Danish Microbiology Database, all patients 
swabbed at the general practitioner’s (GP) or at hospi-
tal and tested for influenza A and B viruses by PCR are 
registered in real time [2]. During the influenza season, 
national guidelines recommend that patients belonging 
to risk groups, including the elderly who present with 
influenza symptoms at GPs and hospitals are swabbed 
and tested for influenza. At hospitals, all patients with 
lower respiratory infections are also recommended 
to be swabbed. All diagnostic influenza tests from 
patients aged 65 years and older were included in this 
study. 
Influenza symptoms were defined as sudden onset 
of fever, muscle ache and upper airway symptoms. 
The trivalent influenza vaccine (TIV) is offered free of 
charge to Danish citizens 65 and older between week 
40 and week 53, and date of vaccination is registered 
in the Danish Vaccination Register [3]. In The Danish 
National Hospital Register, data on all hospital admis-
sions are collected [4]. Comorbidities that can lead to 
severe influenza disease and were diagnosed between 
October 2010 and October 2015 were extracted from 
the Danish National Hospital Register.
Data from the Danish Microbiology Database, the 
Danish Vaccination Register and the Danish National 
Hospital Register were linked using unique identifiers.
Case definitions and statistical analysis
Cases were defined as patients who tested positive for 
influenza A(H1N1)pdm09 or influenza B, and a patient 
was only included the first time a test was positive for 
either type. Controls were patients who tested nega-
tive for both influenza A and B. Patients were consid-
ered vaccinated if they had received the TIV at least 
two weeks before the sample was taken. A logistic 
regression model was used to estimate VE against 
influenza A(H1N1)pdm09 and influenza B using the 
test-negative case–control design (1-OR) × 100%. The 
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estimates were adjusted for sex and co-morbidities 
diagnosed within a five-year period before the 2015/16 
influenza season. Among 195 subtyped influenza A iso-
lates from patients aged 65 years and older, less than 
10% (n = 18) were A(H3N2) and VE against this subtype 
was not estimated.
The statistical programme SAS version 9.4 was used for 
the descriptive and statistical analyses (SAS Institute, 
Cary, United States).
Influenza virus characterisation
All influenza samples received at The National 
Influenza Center in Denmark (NIC) were screened for 
influenza virus by an in-house multiplex real-time 
reverse-transcriptase PCR (qRT-PCR), with primers 
and probes detecting influenza A and B virus as well 
as subtypes of H3 haemagglutinin (HA) and N1pdm09 
neuraminidase. Subtyping of influenza B virus is also 
performed by an in-house duplex qRT-PCR which dif-
ferentiates between the Yamagata and Victoria lineage 
on a fragment of the HA gene.
Sequencing of the HA gene of influenza A(H1N1)pdm09 
and influenza B viruses was performed on extracted 
viral RNA from 62 and 20 samples, respectively. Total 
nucleic acid was extracted using 200 µl of sample 
material and the MagNA Pure LC Total Nucleic Acid 
Isolation Kit on the MagNa Pure 96/32 (Roche). RT-PCR 
of the complete HA gene was performed using in-
house primers and an in-house one-step RT-PCR pro-
gramme on a TRIO cycler (Biometra). Sequencing was 
performed by using Big Dye chemistry on an ABI3500 
capillary sequencer (Thermo Fisher). Assembly of con-
tigs was done in Bionumerics version 6.6 (Applied 
maths) and alignment and phylogenetic analysis were 
conducted with MEGA version 6 [5]. For alignment, the 
Muscle algorithm was used and phylogenetic trees 
were created by the maximum likelihood method using 
1,000 bootstrap replicates. Sequences were also ana-
lysed by BLAST at NCBI GenBank, the Global Initiative 
on Sharing All Influenza Data (GISAID) and at the 
FLUSERVER [6]. The authors gratefully acknowledge the 
59 originating and submitting laboratories who con-
tributed sequences used in the phylogenetic analysis 
to GISAID (www.gisaid.org).
Virus isolation was successful for 32 influenza A(H1N1)
pdm09 and 13 influenza B samples by standard proce-
dures in confluent monolayers of MDCK and/or MDCK-
SIAT cells [7]. Several samples were shipped in E-swab 
medium which is cytotoxic and therefore is challenging 
for virus isolation [8]. Antigenic characterisation was 
performed by HA inhibition (HAI) test [7] using refer-
ence ferret antiserum against A/California/07/2009 
(H1N1pdm09), B/Brisbane/60/2008 (Victoria lineage) 
and B/Phuket/3073/2013 (Yamagata lineage) provided 
Figure 1
Trivalent influenza vaccines received (n = 1,831) and laboratory-confirmed influenza A(H1N1)pdm09 
and B cases among tested patients ≥ 65 years (n = 468), Denmark, 28 September 2015–9 March 2016 
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Influenza vaccines are given free of charge to the elderly 65 years and older from 1 October to 31 December. Due to delay in registration of 
vaccinations, data from week 53 were not available at the time this analysis was performed.
In weeks 40 to 53, between 0 and two influenza A(H1N1) and B cases were registered per week (not visible at presented range of the y-axis).
3www.eurosurveillance.org
Figure 2
Phylogenetic tree of the haemagglutinin gene with reference viruses for the different phylogenetic clades 
of H1N1pdm09 influenza A viruses (n = 40)
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The Danish viruses are indicated with a black circle. A subclade formed by viruses with the amino acid substitutions S101N, S179N and I233T, 
subclade 6B.1, is indicated as well as the subclade formed by viruses with the V169T, V190I, E508G and D518E substitutions, subclade 6B.2. 
The authors gratefully acknowledge the 59 originating and submitting laboratories who contributed sequences used in the phylogenetic 
analysis to GISAID (www.gisaid.org).
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by the World Health Organization (WHO) Collaboration 
Centre, Mill Hill, London.
Vaccine effectiveness results
By 9 March 2016, 3,831 patients 65 years and older 
were tested for influenza A(H1N1)pdm09 and B, and 
65% of them were swabbed at a hospital. In total, 177 
patients were positive for influenza A(H1N1)pdm09 and 
291 for influenza B. In total, 1,505 (82%) of 1,831 study 
participants had received the TIV before 2 November in 
2015 (Figure 1).
Vaccine coverage in cases diagnosed with influenza 
A(H1N1)pdm09 was 37.8%, which is lower than the 
coverage in controls (48.3%), cases diagnosed with 
influenza B (46.4%) (Table) and the estimated national 
coverage of 44% (data not shown). The coverage, for 
both cases and controls, was higher among patients 
with comorbidities compared with patients without 
comorbidities (Table).
Adjusted interim VE among those aged 65 years and 
older against influenza A(H1N1)pdm09 was 35.0% 
(95% confidence interval (CI): 11.1–52.4) and against 
influenza B 4.1% (95% CI: −22.0 to 24.7).
Virus characterisation results
Full gene sequencing of the HA gene from 62 influ-
enza A(H1N1)pdm09 samples revealed in 46 of them 
an amino acid substitution at position 179 (H1 com-
plete open reading frame numbering) from serine to 
asparagine, which leads to a potential glycosylation 
site formed by positions 179–181 with the amino acid 
motif asparagine–glutamine–serine (NQS) (Table). 
Additional substitutions were revealed at amino acid 
position S101N and I233T in the 46 samples having the 
S179N. Two of the patient samples had an additional 
substitution at H155Y. Nine samples had a different 
amino acid motif with substitutions at positions V169T, 
V190I, E508G and D518E.
Phylogentic analysis revealed that all 62 sequenced HA 
genes of A(H1N1)pdm09 viruses belonged to genetic 
clade 6B (Figure 2), however, the 46 viruses with the 
S101N, S179N, and I233T substitutions formed their 
own subclade which now is categorised by the WHO 
as subclade 6B.1. In addition, the nine V169T, V190I, 
E508G and D518E viruses clustered together with the 
A/Minnesota/32/2015(H1N1pdm09) virus (Figure 2) 
and are now categorised as subclade 6B.2.
Of the 32 A(H1N1)pdm09 viruses isolated in cell culture, 
25 belonged to subclade 6B.1, three belonged to sub-
clade 6B.2, and four belonged to clade 6B. Antigenic 
characterisation showed all 32 virus isolates to be 
equally inhibited or inhibited to a lesser extent (two- 
to fourfold decrease in HAI titre), by ferret antiserum 
against A/California/07/2009 (H1N1pdm09) compared 
with the A/California/07/2009 (H1N1pdm09) reference 
virus HAI titres.
Of 447 influenza B virus samples from all age groups 
received for the national influenza surveillance pro-
gramme at NIC Denmark by mid-March 2016, 350 were 
subtyped; 307 (88%) belonged to the B-Victoria line-
age and 43 (12%) belonged to the B-Yamagata lineage. 
The HA genes of 15 B-Victoria viruses were sequenced 
and all belonged to clade 1A, corresponding to the 
Table
Laboratory-confirmed influenza A(H1N1)pdm09 and B cases (n = 468) and influenza A and B test-negative controls 
(n = 3,363) aged ≥ 65 years by trivalent influenza vaccination status, age group and sex, and vaccination coverage among 
influenza cases and controls by age group and sex, Denmark, 28 September 2015–9 March 2016
Characteristic
Influenza A(H1N1)pdm09 Influenza B Controls
Vaccinated 
(n)
Not 
vaccinated 
(n)
Vaccination 
coverage 
(%)
Vaccinated 
(n)
Not 
vaccinated 
(n)
Vaccination 
coverage 
(%)
Vaccinated 
(n)
Not 
vaccinated 
(n)
Vaccination 
coverage (%)
Age group
65–69 16 42 27.6 37 42 46.8 337 488 40.8
70–74 20 29 40.8 37 41 47.4 385 458 45.7
75–79 18 22 45.0 27 34 44.3 363 323 52.9
≥ 80 13 17 43.3 34 39 46.6 544 466 53.9
Comorbidities
No 15 34 30.6 36 66 35.3 347 480 42.0
Yes 52 76 40.6 99 90 52.4 1,282 1,255 50.5
Sex
Female 28 45 38.4 70 79 50.0 780 865 47.4
Male 39 65 37.5 65 77 45.8 849 869 49.4
Total 67 110 37.8 135 156 46.4 1,629 1,734a 48.3
a Sex was not known for one person.
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strain included in the quadrivalent vaccine but not 
included in the trivalent vaccine used in Denmark in 
the current season. Antigenic characterisation by HAI 
test of 13 virus isolates showed a two- to fourfold 
decrease in HAI-titre using the ferret antiserum against 
B/Brisbane/60/2008 compared with the vaccine refer-
ence virus B/Brisbane/60/2008. None of the B-Victoria 
viruses was inhibited by the B-Yamagata reference 
antiserum B/Phuket/3073/2013.
Discussion
Due to the late start of the influenza season in Europe 
only few interim VE estimates have been published 
[9,10] and in particular, little information is avail-
able on the VE in those aged 65 years and older, an 
important target group for influenza vaccination. 
Furthermore, a mismatch was observed between the 
circulating B-Victoria lineage and the B-Yamagata line-
age included in the TIV for the northern hemisphere.
We found no effect of the TIV against influenza B 4.1% 
(95% CI: −22.0 to 24.7), which accounted for 62% of 
the influenza detections in patients aged 65 years 
and older in Denmark until 9 March 2016. This can 
be explained by the mismatch because 88% of the B 
infections were Victoria lineage. This is in line with 
findings from Hong Kong in 2011/12 where B-Victoria 
was included in the vaccine and VE against paediatric 
influenza B-Yamagata hospitalisation was estimated 
at 9.5% (95% CI: −240.4 to 76.0) [11]. However, in the 
same season, a study from the United States esti-
mated a VE of 66% (95%CI: 38–81) against B-Yamagata 
although only the B-Victoria lineage was included in 
the vaccine [12], which could suggest cross-protection 
between lineages. Antigenic characterisation at the 
Danish NIC supports a lack of cross-reactivity between 
B-Yamagata and B-Victoria when using the current sea-
son’s vaccine antiserum against B/Brisbane/60/2008 
and B/Phuket/3073/2013 in the HAI test which is also 
reported in the study from Hong Kong [11]. Influenza B 
lineage-specific TIV VEs have earlier been estimated 
in seasons with both mismatch and/or cocirculation of 
two influenza B lineages.  Some VE studies have sug-
gested cross-protection between lineages and others 
not. The reasons for these differences are not known 
but may be explained by methodological issues or by 
differences in population immunity due to variations in 
vaccination strategies or differences in circulating line-
ages between regions [13].
It is likely that immunity against influenza B Victoria 
in the Danish population is low, as only few isolates 
from this lineage have been detected in Denmark since 
2010/11 and have not been included in the vaccine 
since 2011/12. Influenza B-Victoria also dominates over 
B-Yamagata in the rest of Europe [14], and if the quad-
rivalent vaccine had been used instead of TIV during 
the current season morbidity due to influenza B might 
have been lower.
We found a moderate to low VE against influenza 
A(H1N1)pdm09 of 35.0% (95% CI: 11.1–52.4) in patients 
aged 65 years and older, although the majority of influ-
enza A(H1N1)pdm09 circulating in Denmark in the 
2015/16 season belonged to the new genetic subclade 
6B.1. VE against influenza A(H1N1)pdm09 in the current 
season was similar to the VE against influenza A(H1N1)
pdm09 in the 2014/15 season in Denmark of 31% (95% 
CI: −0.7 to 52.7) where 114 patients were positive for 
influenza A(H1N1)pdm09 and 3,351 patients tested 
negative (data not shown). This estimate also corre-
sponds to the estimated VE of 22% (95% CI: −44.4 to 
58.4) against influenza A(H1N1)pdm09 in the same age 
group in season 2014/15 reported by I-Move following 
a multicentre case–control study [15].
Conclusion
We estimated similar VE against influenza A(H1N1)
pdm09 in season 2014/15 and 2015/16 in those aged 
65 years and older in spite of the occurrence of the new 
subclade 6B.1. This is reassuring as the WHO recom-
mendations for the influenza A(H1N1)pdm09 compo-
nent in the 2016/17 vaccine for the northern hemisphere 
remained the same as in previous years, while the 
influenza B component changed from Yamagata to 
Victoria [16].
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